Treximet in the Treatment of Chronic Migraine

Status Completed

Clinical Trial Summary

This study is being conducted to evaluate the hypothesis that use of Treximet in patients with chronic migraine, when used on a short term daily basis and as rescue for break through attacks, will reduce migraine frequency and impact.

Clinical Trial Description

One investigative center will enroll 40 subjects in the US.

At Visit 1, following informed consent, a medical, migraine, and medication history will be collected and a physical and neurological exam with vital signs will be performed. A 12-lead ECG will be completed. Eligible subjects will complete a 1-month Baseline Period and treat migraine with their current preferred treatment of choice. Throughout the study, subjects will complete daily Headache Diaries reporting headache severity and associated symptoms with use of study medication in each 30-day period.

At Visit 2, subjects continuing to meet eligibility criteria will be randomized 1:1 to Treximet or naproxen and provided with medication to treat daily for 30 days. At Visits 3 and 4 subjects will be provided with study medication to treat on 14 or fewer days per month. Subjects will be encouraged to treat their migraine attacks within 1 hour of onset of headache pain and while the pain is still mild. Adverse events will be collected beginning from the first dose of study medication. Subjects exit the study at Visit 5 after a 3-month Treatment Period.

The study provides opportunity to evaluate the usefulness of patient education with a 15-minute digital versatile disc (DVD) concerning the processes of headache evolution and lifestyle changes for better headache management. At Visit 2, subjects will view the DVD in-clinic with a copy provided for at-home viewing. Subjects will complete a Lifestyle Choices for Better Migraine Management Questionnaire at each visit and receive 3 copies to be completed weekly and returned at the following visit.

The Migraine Disability Assessment questionnaire (MIDAS) will be completed at Visits 2 and 5 to determine the level of pain and disability caused by headache. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01090050
Study type	Interventional
Source	Cady, Roger, M.D.
Contact
Status	Completed
Phase	Phase 4
Start date	September 2010
Completion date	July 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05720819` - Biofeedback-VR for Treatment of Chronic Migraine	N/A
Not yet recruiting	`NCT06428838` - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context	Phase 3
Recruiting	`NCT05517200` - Pilot Study for a Machine Learning Test for Migraine
Recruiting	`NCT05891808` - miR-155 Expression in Episodic and Chronic Migraine
Completed	`NCT02514148` - Biobehavioral Physical Therapy Strategies Based on Therapeutic Exercise Applied to Chronic Migraine Patients	N/A
Enrolling by invitation	`NCT02291380` - A Study to Evaluate Botulinum Toxin Type A for Injection（HengLi®）for Prophylactic Treatment of Chronic Migraine	Phase 3
Withdrawn	`NCT02122744` - RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine	N/A
Completed	`NCT02122237` - Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial	Phase 3
Recruiting	`NCT02202486` - Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI	N/A
Completed	`NCT01709708` - Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine	Phase 4
Completed	`NCT01741246` - Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging	N/A
Recruiting	`NCT03507400` - Introvision for Migraine and Headaches	N/A
Completed	`NCT04161807` - Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine	N/A
Completed	`NCT03175263` - OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial Pain	N/A
Withdrawn	`NCT04353505` - Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache	Phase 1
Completed	`NCT01667250` - Non-Invasive Neurostimulation for the Prevention of Chronic Migraine	N/A
Completed	`NCT01700387` - A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency	Phase 4
Not yet recruiting	`NCT01135784` - Study of MIGRA-ZEN RELIEF PLUS In the Treatment of Chronic Migraine Headache	Phase 2
Completed	`NCT00772031` - NINDS CRC Chronic Migraine Treatment Trial	Phase 3
Completed	`NCT01496950` - Double-blind Randomized Clinical Trial of Transcranial Magnetic Stimulation in Chronic Migraine	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.